Caracol Radio [5 May 2018]
“Más del 90% de pacientes con Chagas se diagnostican en etapa crónica” – “More than 90% of patients with Chagas disease are diagnosed in the chronic stage”
El Independiente [21 April 2018]
“En Argentina nacen cada año no menos de 1.300 niños con Chagas” – “In Argentina, no less than 1,300 children are born each year with Chagas disease”
Caracol Radio [14 April 2018]
“Minsalud desarrolla acuerdo para garantizar la atención integral de Chagas” – “Ministry of Health develops agreement to guarantee comprehensive Chagas attention”
Bogotá, Colombia – 14 April 2018
Objective is to improve access to diagnosis and treatment of people affected by this disease
An agreement to facilitate and strengthen access to diagnosis and treatment of patients with Chagas and other diseases of public health interest has been signed by the Colombian Ministry of Health and Social Protection and the non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi).
Infobae [13 April 2018]
“Día Mundial del Chagas: ‘Aún no se detecta al 50 por ciento de los bebés que nacen con Chagas'” – “World Chagas Day: ‘We still don’t detected 50 percent of babies born with Chagas'”
Buenos Aires, Argentina – 13 April 2018
Argentina has approved the paediatric indication of a drug used for treatment of Chagas disease, benznidazole, which will now be available in 12.5 mg pills, the dose required to treat children under the age of 2. The indication was approved by the Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT).
Healio [8 April 2018]
“International partnership invests $15.5 million to combat neglected tropical diseases, TB, malaria”
31 May – 2 June 2018
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – session on etiological treatment on chronic phase of Chagas disease
24-26 May 2018
Jayme Fernandes, Senior CRA, DNDi Latin America – presentation on innovation in the field of Chagas and leishmaniasis treatments
23-25 May 2018
Poster on the mechanism of action of an experimental drug against Chagas disease
The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.
Daiichi Sankyo RD Novare and DNDi are pleased to announce the financial support of the Japan Global Health Innovative Technology Fund to their new collaboration on natural products.
Geneva / Brentford / Dundee – 27 March 2018
The not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with GlaxoSmithKline (GSK), and the University of Dundee Drug Discovery Unit (DDU), in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.
ABC Agencia [8 March 2018]
“Reclaman detener transmisión madre-hijo de Chagas para controlar enfermedad” – “They claim to stop Chagas’ mother-child transmission to control the disease”
El País [20 February 2018]
“Chagas, enfermedad silenciosa que aqueja al pueblo tarijeño” – “Chagas, a silent disease that afflicts the people of Tarija”
7th Edition: Precision Global Health in the Digital Age
10-12 April 2018
Bernard Pécoul, Executive Director – plenary talk on emerging infectious diseases crisis
Digas Ngolo, Investigator Coordinator, DNDi Africa – parallel session on ehealth
8 March 2018
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation about control programmes for congenital Chagas disease
Michel Lotrowska, Acting Regional Director, DNDi Latin America – participation in the annual meeting Chagas coalition
by Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, Almeida IC, Alves F, Strub-Wourgaft N, Ribeiro I.
The Lancet Infectious Diseases, January 2018